Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
21SEP

J&J backs Trimtech seed to £35.6m

2 min read
16:52UTC

Trimtech Therapeutics extended its seed round to £35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

← Back to Nscale takes $103.4bn of contracts to NYSEJump to analysis ↓
TechnologyDeveloping
Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to £35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture arm, and BGF, a UK growth-capital investor, added $14m and both took board seats 1. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a £25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline : a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

Sources:UKTN
Mentions:Laverock Therapeutics →Johnson & Johnson Innovation (JJDC) →BGF →Cambridge Innovation Capital →Cambridge →Conduct →SAP →Trimtech Therapeutics →
First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026
Read original →
Causes and effects
Caused by
Conduct takes $60m as SAP buys in
SAP's strategic stake in Conduct set the template of a corporate investor buying board-seat visibility, now repeated with J&J Innovation and BGF in Trimtech.
Occurred 17 Jun 2026
Read story →
This Event
J&J backs Trimtech seed to £35.6m
Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.
Different Perspectives
Nscale and Open Cosmos
Nscale and Open Cosmos
Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.
The Entrepreneurs Network
The Entrepreneurs Network
The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.
New Economics Foundation
New Economics Foundation
The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.
Competition and Markets Authority
Competition and Markets Authority
The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.